Načítá se...

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)

The discovery of asunaprevir (1) began with the concept of engaging the small and well-defined S(1)’ pocket of the hepatitis C virus (HCV) NS3/4A protease that was explored in the context of tripeptide carboxylic acid-based inhibitors. A cyclopropyl-acyl sulfonamide moiety was found to be the optima...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:HCV: The Journey from Discovery to a Cure
Hlavní autoři: Meanwell, Nicholas A., Rajamani, Ramkumar, Scola, Paul M., Sun, Li-Qiang
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7123690/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/7355_2018_58
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!